MorphoSys extends antibody alliance with Schering-Plough
MorphoSys and Schering-Plough have extended their current collaboration for another year. The partnership, initiated in May 2006, may be extended by Schering-Plough annually until 2011.
MorphoSys and Schering-Plough have extended their current collaboration for another year. The partnership, initiated in May 2006, may be extended by Schering-Plough annually until 2011.
The agreement grants Schering-Plough continued access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site, Schering-Plough Biopharma in Palo Alto, California, and contains options for therapeutic licences.
For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive licence fees, plus milestone payments and royalties on HuCAL antibodies developed under the agreement. Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.